Lv7
4090 积分 2021-03-30 加入
A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos
1小时前
待确认
RF4 (MUM1) in B-cell malignancies: molecular mechanisms, biological functions, and clinical implications
2小时前
待确认
IRF4 in multiple myeloma—Biology, disease and therapeutic target
5小时前
待确认
Exposure‐Response Analysis to Assess the Concentration‐QTc Relationship of Iberdomide
18小时前
待确认
Evaluation of iberdomide and cytochrome p450 drug-drug interaction potential in vitro and in a phase 1 study in healthy subjects
18小时前
待确认
Mezigdomide and Multiple Myeloma
19小时前
待确认
A Phase I, Open-Label, Mass Balance Study of [14C]-Iberdomide in Healthy Subjects
20小时前
待确认
Mezigdomide for multiple myeloma: a focus on phase 2 trial data
20小时前
待确认
Application of Physiologically Based Pharmacokinetic Modeling to Inform Dose Selection of Mezigdomide in a Phase I Drug–Drug Interaction Study
20小时前
待确认
An immunostimulatory CELMoD combination overcomes resistance to T-cell engagers caused by a high multiple myeloma burden
20小时前
待确认
皖公网安备34019202002308
